Revvity (NYSE:RVTY) Announces Earnings Results

Revvity (NYSE:RVTY) released its earnings results on Tuesday. The company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04, FiscalAI reports. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The firm had revenue of $711.12 million during the quarter, compared to analyst estimates of $704.07 million. During the same quarter in the previous year, the business earned $1.01 EPS. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. Revvity updated its FY 2026 guidance to 5.200-5.300 EPS.

Here are the key takeaways from Revvity’s conference call:

• Signed a letter of intent to divest the China immunodiagnostics business (≈6% of 2025 revenue), expects a definitive agreement within ~2 months and closing by end of 2027, and says the move will reweight China to ~8%–9% of revenue and boost 2026 pro forma organic growth ~100 bps and margins ~30 bps.
• Revvity beat Q1 expectations with 3% organic growth, adjusted operating margin of 23.6% and adjusted EPS of $1.06; excluding the China immunodiagnostics business, Q1 pro forma results would have been ~6% organic growth and a 24% pro forma margin.
• Software and AI are core growth drivers: the company launched Xynthetica, BioDesign, and LabGistics this year, reports SaaS/ARR growth north of 30%–40% year‑over‑year and says internal AI deployment (cited by Gartner) is accelerating product delivery and employee productivity.
• Balance sheet and cash generation remain strong — Q1 free cash flow was $115M (≈97% conversion of adjusted net income), the company repurchased $86M of stock in the quarter, finished with net leverage ~2.8x and plans to repay a ~€600M bond in July.
• Near‑term financial impact: management lowered reported 2026 adjusted EPS by roughly $0.15 to a pro forma range of $5.20–$5.30 (the guide excludes any sale proceeds), and the planned divestiture reduces previously expected 2026 revenue by ~4.5%, creating short‑term dilution and timing uncertainty until closing.

Revvity Stock Up 0.9%

RVTY traded up $0.91 during trading on Thursday, hitting $100.00. The company had a trading volume of 116,636 shares, compared to its average volume of 1,279,291. The company has a market capitalization of $11.18 billion, a PE ratio of 47.63, a PEG ratio of 1.96 and a beta of 1.05. Revvity has a one year low of $81.22 and a one year high of $118.30. The firm’s 50-day moving average price is $90.28 and its 200 day moving average price is $96.86. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.37.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 7th. Investors of record on Friday, July 17th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Friday, July 17th. Revvity’s payout ratio is currently 13.40%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Barclays reaffirmed an “equal weight” rating and set a $95.00 target price (down from $118.00) on shares of Revvity in a report on Tuesday, April 14th. Robert W. Baird set a $117.00 price target on shares of Revvity in a report on Wednesday. Stifel Nicolaus decreased their price target on shares of Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a report on Wednesday. Weiss Ratings lowered shares of Revvity from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 18th. Finally, Jefferies Financial Group boosted their price target on shares of Revvity from $100.00 to $105.00 and gave the company a “hold” rating in a report on Monday, February 2nd. Four research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $106.82.

Institutional Investors Weigh In On Revvity

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its position in Revvity by 5.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,606,637 shares of the company’s stock worth $832,693,000 after buying an additional 434,570 shares in the last quarter. Morgan Stanley lifted its position in Revvity by 29.6% during the 4th quarter. Morgan Stanley now owns 2,844,464 shares of the company’s stock worth $275,202,000 after buying an additional 650,083 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Revvity by 22.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,612,116 shares of the company’s stock worth $252,727,000 after buying an additional 486,159 shares in the last quarter. Invesco Ltd. lifted its position in Revvity by 15.7% during the 3rd quarter. Invesco Ltd. now owns 2,553,515 shares of the company’s stock worth $223,816,000 after buying an additional 346,313 shares in the last quarter. Finally, UBS Group AG increased its stake in shares of Revvity by 22.3% during the 3rd quarter. UBS Group AG now owns 2,179,505 shares of the company’s stock worth $191,034,000 after purchasing an additional 397,160 shares during the last quarter. 86.65% of the stock is owned by institutional investors.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.